Section Arrow
CARA.NASDAQ
- Cara Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/05/16 16:12 EDT
Last
 0.8052
+0.0453 (+5.96%)
Day High 
0.87 
Prev. Close
0.7599 
1-M High
0.8315 
Volume 
491.71K 
Bid
0.7923
Ask
0.8003
Day Low
0.7255 
Open
0.7371 
1-M Low
0.6311 
Market Cap 
41.54M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.76 
20-SMA 0.73 
50-SMA 0.81 
52-W High 4.45 
52-W Low 0.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.19/-0.81
Enterprise Value
47.63M
Balance Sheet
Book Value Per Share
1.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.97M
Operating Revenue Per Share
0.50
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1001+0.0224+28.83%-- 
DNAGinkgo Bioworks Holdings0.839-0.0001-0.01%-- 
NBYNovaBay Pharmaceuticals0.12+0.0155+14.83%-- 
JAGXJaguar Health0.2867+0.0316+12.39%-- 
NVAXNovavax14.4+1.5+11.63%-- 
Quotes are at least 15-min delayed:2024/05/16 16:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.